Ulcerative Colitis
Conditions
Brief summary
Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
Detailed description
Participants will undergo screening for study, if eligible, participants will be dosed with 15 million or 30 million cells will be administered via IA delivery with interventional radiology. Participant study visits after study intervention includes visits on: Day 1, Week 1, Week 2, Week 8, Week 24, Week 52, and Week 104.
Interventions
DRUGAdipose derived, autologous mesenchymal stem cells
Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Males and Females 18-65 years of age. * Moderate to Severe medically refractory inflammatory ulcerative colitis: * as defined by a an Adapted Mayo Score of 5to 9 points * including an endoscopic sub-score of 2 or 3 * Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, anti-TNF, and anti-integrin therapy are permitted. * To meet the definition of refractory UC, all patients must have failed at least 2 standard FDA approved medications for the treatment of UC * Current standard therapy includes 5-ASA products, thiopurines, anti-TNF therapy, ustekinemab, vedolizumab, and tofacitinib (i.e. all FDA approved therapies for UC). * Refractory and failure to response is defined as continued symptoms despite 12 weeks of therapy at FDA approved doses by product necessitating change in medical strategy or referral for colectomy. * All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition * Female subjects that are of child bearing potential must to agree to use effective contraception method(s) for the duration of the study * Hemoglobin must be greater than 8 * INR must be less than 1.5 * Ability to comply with protocol * Competent and able to provide written informed consent
Exclusion criteria
* Inability to give informed consent. * Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient. * Specific exclusions; Known history of hepatitis B, C, or HIV * Patients that have had a partial colectomy * Patients that have underlying vasculitis or have been diagnosed with an underlying condition that predisposes to developing blood clots. * History of cancer including melanoma (with the exception of localized skin cancers) * Investigational drug within thirty (30) days of baseline * History of clinically significant auto-immunity (other than UC) or any previous example of fat-directed autoimmunity. Note that auto-immmunity is defined as a systemic immune mediated disease for which the antigen is known or unknown. Autoimmune diseases other than UC are excluded. Extraintestinal manifestations of UC (specifically joint inflammation, eye inflammation, PSC, skin manifestations- i.e. pyoderma gangrenosum, erythema nodosum) will be allowable. * Allergic to local anesthetics * Pregnant patients or trying to become pregnant or breast feeding. * Neoplasia of the colon and preoperative biopsy * C. Difficile infection within 30 days of study injection * Diagnosis of indeterminate colitis or suspicion of CD * Subjects with fulminant colitis, toxic megacolon, with ostomy, or ileoanal pouch * History or demonstration of pathology related to adipose tissue * Any other indication determined by the PI to be counter indicated for participation on this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events | 24 months | Evaluate safety by assessment of adverse events defined as worsening (change in nature, severity, or frequency of bowel movements, bleeding per rectum, or tenesmus) of UC present at the time of the study, intercurrent illnesses, abnormal laboratory values (this includes clinically significant shifts from baseline within the range of normal that the investigator considers to be clinically significant) or clinically significant abnormalities in physical examination, vital signs, weight, frequency of bloody stools or change in stools. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with mucosal healing | 6 months | Mucosal appearance at endoscopy via Adapted Mayo Score (defined as score of 0 or 1) |
| Number of participants with clinical symptom response | 24 months | To assess the clinical symptom response of luminal healing induced by the intra-arterial delivery of autologous AD-MSCs for the treatment of UC. Using the validated via Adapted Mayo Score (decrease from Baseline ≥ 2 points and ≥ 30%, including a decrease in rectal bleeding sub-score ≥ 1 or an absolute rectal bleeding sub-score ≤ 1) |
| Number of participants with improved healing on pathology | 24 months | Histopathology: Improved healing on surgical pathology (colectomy specimen or post-intervention colonic biopsies) as compared to pre-operative endoscopic biopsies |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORWilliam Faubion, MD
Mayo Clinic
Outcome results
None listed